Enrique Arredondo1, George Udeani2 and Salim Surani3*
1Second-Year Professional Student, Irma Lerma Rangel College of Pharmacy, Texas A&M University, Texas, USA
2Head and Clinical Professor, Department of Pharmacy Practice, Irma Lerma Rangel College of Pharmacy, Texas A&M University, Texas, USA
3Adjunct Clinical Professor, Texas A&M University, Texas, USA
*Corresponding Author: Salim Surani, Adjunct Clinical Professor, Texas A&M University, Texas, USA.
Received: October 19, 2020; Published: November 25, 2020
With the coronavirus disease 19 (COVID-19) causing a health crisis worldwide, researchers and clinicians are exploring different pharmacological treatments to fight against this pandemic. A leading class of drugs currently being experimented with to treat, prevent, or decrease the severity of COVID symptoms are monoclonal antibodies. Many pharmaceutical companies are constructing monoclonal antibodies by utilizing the antibodies produced by patients infected with COVID. By analyzing the antibodies' structure and using the mechanism of action of how COVID infects the host, specific and compelling monoclonal antibodies targeting the virus's pathway to infect the cells can be constructed. Regeneron and Eli Lilly and Company are two leading pharmaceutical companies currently working on monoclonal antibodies. Regeneron is currently working on a combination monoclonal antibody known as REGN-COV2. The combination therapy has shown to reduce both viral levels and improve symptoms in non-hospitalized patients. In contrast, Eli Lilly and Company's combination of bamlanivimab and etesevimab has shown to reduce viral load, symptoms, COVID-related hospitalization, and emergency room hospitalizations. This minireview aims to bring awareness of the different clinical trials involving monoclonal antibodies and their current status.
Keywords: Monoclonal Antibody; Neutralizing Antibodies; COVID-19; SARS-CoV-2; Regeneron; Bamlanivimab; Etesevimab; REGN-COV2
Citation: Salim Surani., et al. “COVID Monoclonal Antibodies and Current Research: Are We There Yet?". Acta Scientific Medical Sciences 4.12 (2020): 74-80.
Copyright: © 2020 Salim Surani., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.